Research Paper Volume 15, Issue 20 pp 11554—11570
Comprehensive analysis of transcriptome data and experimental identification show that solute carrier 35 member A2 (SLC35A2) is a prognostic marker of colorectal cancer
Figure 3. Analysis of pan-cancer SLC35A2 expression and survival analysis of methylation site cg26807389 related to SLC35A2 with CRC patients. (A) Differential expression of SLC35A2 was found in various tumor and normal tissues in TIMER database. Among them, the expression of SLC35A2 was elevated in colorectal adenocarcinoma (COAD) and rectal adenocarcinoma (READ). (*p < 0.05, **p < 0.01, ***p < 0.001). (B) Survival analysis of high expression group of methylation site cg26807389. The results showed that CRC patients with high expression of methylation site cg26807389 had poor prognosis (p = 0.021).